信迪利单抗联合贝伐珠单抗联合肝动脉化疗栓塞术治疗不可切除肝癌的疗效及对血清肿瘤相关因子的影响

Sintilimab Injection, Bevacizumab with Transcatheter ArterialChemoembolization on the Surgical Effects and Serum TumorMarkers for Unresectable Liver Cancer Patients

目的 分析信迪利单抗、贝伐珠单抗及肝动脉化疗栓塞术(TACE)联用对不可切除肝癌的疗效和血清肿瘤相关因子的影响。方法 回顾性分析2021年1月至2022年6月开封市肿瘤医院收治的62例不可切除的肝癌患者临床资料,根据不同治疗方式分成对照组(仅予以TACE)、观察组(在前组基础上加以信迪利单抗、贝伐珠单抗),各31例。比较两组的疗效,治疗前后血清肿瘤相关因子甲胎蛋白(AFP)、癌胚抗原(CEA)、糖链抗原(CA199)、谷氨酰胺转肽酶(GGT)水平,副反应出现情况。结果 观察组病情控制率(83.87%)高于对照组(51.61%),差异有统计学意义(P <0.05)。治疗前,两组患者血清中AFP、CEA、CA199、GGT水平差异无统计学意义(P> 0.05);治疗后,两组患者血清中AFP、CEA、CA199、GGT水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P <0.05)。两组患者转氨酶上升、栓塞综合征、发热、胃肠道反应、免疫相关不良反应(肺炎)比较,差异无统计学意义(P> 0.05)。结论 信迪利单抗、贝伐珠单抗及TACE联用对不可切除肝癌疗效理想,能降低患者血清肿瘤相关因子水平,且不会显著增加副反应出现,安全性高。

Objective To analyze the impact of sintilimab injection,bevacizumab with transcatheter arterial chemoembolization(TACE)on the surgical effects and serum tumor markers for unresectable liver cancer patients.Methods Clinical data about 62 unresectable liver cancer patients from January 2021 to June 2022 treated in Kaifeng Tumor Hospital was retrospectively analyzed.According to different treatment modes,patients were divided into control group(N=31)and observation group(N=31).TACE was applied in the control group;TACE,Sintilimab injection and Bevacizumab were applied in the observation group.Group contrast results were obtained through the surgical effects,serum alpha fetoprotein(AFP),carcino-embryonic antigen(CEA),carbohydrate antigen199(CA199),gamma-glutamyl transferase(GGT)and side reactions.Results The disease control rate in the observation group(83.87%)was higher than control group(51.61%),the difference was statistically significant(P<0.05);Before therapy,serum AFP,CEA,CA199 and GGT levels between groups were not significantly different(P>0.05);After therapy,serum AFP,CEA,CA199 and GGT levels in two groups were lower than before;serum AFP,CEA,CA199 and GGT levels in the observation group were even lower than control group,with significant differences(P<0.05);There were no significant differences between the transaminase rise,embolization syndrome,fever,gastrointestinal reaction,and immune-related adverse reactions(pneumonia)between two groups(P>0.05).Conclusion The combination of Sintilimab,Bevacizumab and TACE has ideal efficacy on unresectable liver cancer,and can reduce the serum level of tumor-related factors in patients without significantly increasing the occurrence of side effects,and has a high safety profile.